From Proteopedia
proteopedia linkproteopedia link Pharmacokinetics
| Tyrosine Kinase Inhibitor Pharmacokinetics [1][2]
|
| Parameter
| Lapatinib (Tykerb)
| Sunitinib (Sutent)
| Sorafenib (Nexavar)
|
| Tmax (hr)
| 4
| Sunitinib (Sutent)
| Sorafenib (Nexavar)
|
| Cmax (ng/ml)
| 115
| 24.6
| 460
|
| Bioavailability (%)
| Lapatinib (Tykerb)
| Sunitinib (Sutent)
| Sorafenib (Nexavar)
|
| Protein Binding (%)
| Lapatinib (Tykerb)
| Sunitinib (Sutent)
| Sorafenib (Nexavar)
|
| T1/2 (hr)
| 9.6
| 83
| 29
|
| AUC (ng/ml/hr)
| 1429
| 1921
| 11040
|
| IC50 (nM)
| Lapatinib (Tykerb)
| Sunitinib (Sutent)
| Sorafenib (Nexavar)
|
| Dosage (mg)
| 100
| 50
| 50
|
| Metabolism
| Lapatinib (Tykerb)
| Sunitinib (Sutent)
| Sorafenib (Nexavar)
|
